FR15C0030I2 - Composes d'acide benzoique 1,2,4-oxadiazole et utilisation de ceux-ci dans la suppression non-sens et le traitement de maladies - Google Patents
Composes d'acide benzoique 1,2,4-oxadiazole et utilisation de ceux-ci dans la suppression non-sens et le traitement de maladiesInfo
- Publication number
- FR15C0030I2 FR15C0030I2 FR15C0030C FR15C0030C FR15C0030I2 FR 15C0030 I2 FR15C0030 I2 FR 15C0030I2 FR 15C0030 C FR15C0030 C FR 15C0030C FR 15C0030 C FR15C0030 C FR 15C0030C FR 15C0030 I2 FR15C0030 I2 FR 15C0030I2
- Authority
- FR
- France
- Prior art keywords
- suppression
- diseases
- treatment
- benzoic acid
- acid compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- SNGNHEIIYFNIIL-UHFFFAOYSA-N benzoic acid;1,2,4-oxadiazole Chemical class C=1N=CON=1.OC(=O)C1=CC=CC=C1 SNGNHEIIYFNIIL-UHFFFAOYSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001629 suppression Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46198803P | 2003-04-11 | 2003-04-11 | |
PCT/US2004/011106 WO2004091502A2 (en) | 2003-04-11 | 2004-04-09 | 1,2,4-oxadiazole benzoic acid compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
FR15C0030I1 FR15C0030I1 (da) | 2015-05-22 |
FR15C0030I2 true FR15C0030I2 (fr) | 2015-07-24 |
Family
ID=33299886
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR15C0030C Active FR15C0030I2 (fr) | 2003-04-11 | 2015-04-21 | Composes d'acide benzoique 1,2,4-oxadiazole et utilisation de ceux-ci dans la suppression non-sens et le traitement de maladies |
Country Status (30)
Country | Link |
---|---|
US (17) | US6992096B2 (da) |
EP (9) | EP1618098B1 (da) |
JP (2) | JP4851933B2 (da) |
KR (1) | KR101134188B1 (da) |
CN (2) | CN1802360B (da) |
AU (1) | AU2004229487B9 (da) |
BE (1) | BE2015C025I2 (da) |
BR (1) | BRPI0409319B8 (da) |
CA (1) | CA2521992C (da) |
CR (1) | CR8086A (da) |
CY (6) | CY1115870T1 (da) |
DK (7) | DK1618098T3 (da) |
EA (1) | EA009120B1 (da) |
ES (7) | ES2679108T3 (da) |
FR (1) | FR15C0030I2 (da) |
HK (4) | HK1093979A1 (da) |
HU (7) | HUE059464T2 (da) |
IL (2) | IL171343A (da) |
LU (1) | LU92698I2 (da) |
MA (1) | MA27802A1 (da) |
MX (1) | MXPA05010747A (da) |
NO (2) | NO332843B1 (da) |
NZ (1) | NZ543263A (da) |
PL (7) | PL3103800T3 (da) |
PT (7) | PT2910551T (da) |
SI (7) | SI3889142T1 (da) |
TR (1) | TR201706226T4 (da) |
UA (1) | UA84420C2 (da) |
WO (1) | WO2004091502A2 (da) |
ZA (1) | ZA200508298B (da) |
Families Citing this family (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6458538B1 (en) * | 1999-12-14 | 2002-10-01 | Ptc Therapeutics, Inc. | Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay |
WO2004001010A2 (en) * | 2002-06-21 | 2003-12-31 | Ptc Therapeutics, Inc. | METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY |
US7927791B2 (en) | 2002-07-24 | 2011-04-19 | Ptc Therapeutics, Inc. | Methods for identifying small molecules that modulate premature translation termination and nonsense mediated mRNA decay |
ZA200508298B (en) | 2003-04-11 | 2007-01-31 | Ptc Therapeutics Inc | 1,2,4-oxadiazole benzoic acid compounds |
US8580842B2 (en) | 2003-09-30 | 2013-11-12 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
EP1799659A1 (en) * | 2004-10-13 | 2007-06-27 | PTC Therapeutics, Inc. | Compounds for nonsense suppression, and methods for their use |
AU2012238226B2 (en) * | 2005-04-08 | 2015-05-14 | Ptc Therapeutics, Inc. | Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy |
US8716321B2 (en) * | 2005-04-08 | 2014-05-06 | Ptc Therapeutics, Inc. | Methods for dosing an orally active 1,2,4-oxadiazole |
CN100378084C (zh) * | 2005-08-01 | 2008-04-02 | 安徽大学 | 2,5-二芳基取代基-1,3,4-噁二唑衍生物及其合成方法、用途 |
CN101420963B (zh) * | 2006-02-09 | 2012-09-05 | 安佐制药股份有限公司 | 用于治疗乳腺癌、结肠直肠癌、胰腺癌、卵巢癌和肺癌的7-乙基-10-羟基喜树碱的多臂聚合轭合物 |
MX2008012515A (es) | 2006-03-30 | 2008-11-19 | Ptc Therapeutics Inc | Metodos para la produccion de proteina funcional a partir de adn que tiene una mutacion sin sentido y el tratamiento de trastornos asociados con la misma. |
WO2007116229A1 (en) * | 2006-04-06 | 2007-10-18 | Prosidion Limited | Heterocyclic gpcr agonists |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
PL3091011T3 (pl) | 2006-04-07 | 2018-06-29 | Vertex Pharmaceuticals Incorporated | Modulatory transporterów posiadających kasetę wiążącą ATP |
US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US20070287699A1 (en) * | 2006-05-01 | 2007-12-13 | Virobay, Inc. | Antiviral agents |
NZ598012A (en) * | 2006-09-08 | 2013-08-30 | Ptc Therapeutics Inc | Processes for the preparation of 1,2,4-oxadiazole benzoic acids |
WO2008130370A1 (en) * | 2006-09-25 | 2008-10-30 | Ptc Therapeutics, Inc. | Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and the use for nonsense suppression |
CL2007002743A1 (es) * | 2006-09-25 | 2008-07-11 | Pct Therapeutics Inc Soc Organ | Forma cristalina del acido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]-benzoico; composicion farmaceutica que comprende a dicha forma cristalina; y su uso para modular la terminacion prematura de traslado o decaimiento de marn, tales como carcicoma. |
AU2016262645B2 (en) * | 2006-10-12 | 2018-05-17 | Ptc Therapeutics, Inc. | Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy |
SI2073805T1 (sl) * | 2006-10-12 | 2015-10-30 | Ptc Therapeutics, Inc. | Postopki za odmerjanje peroralno aktivnega 1,2,4-oksadiazola za zdravljenje supresije nesmiselnih mutacij |
AU2013219243B2 (en) * | 2006-10-12 | 2016-09-08 | Ptc Therapeutics, Inc. | Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
US8486979B2 (en) * | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
US20080167286A1 (en) * | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
US20110207704A1 (en) * | 2006-12-15 | 2011-08-25 | Abbott Laboratories | Novel Oxadiazole Compounds |
NZ577111A (en) * | 2006-12-15 | 2012-05-25 | Abbott Lab | Novel oxadiazole compounds |
UY30846A1 (es) | 2006-12-30 | 2008-07-31 | Abbott Gmbh & Amp | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos |
BRPI0809498A2 (pt) * | 2007-04-02 | 2014-09-23 | Inst Oneworld Health | Compostos inibidores de cftr e seus usos |
JP5416103B2 (ja) * | 2007-06-22 | 2014-02-12 | エフ.ホフマン−ラ ロシュ アーゲー | イソオキサゾール−イミダゾール誘導体 |
AU2008278824A1 (en) * | 2007-07-23 | 2009-01-29 | Biomarin Iga Limited | Compounds for treating Duchenne muscular dystrophy |
JP2010535708A (ja) | 2007-08-03 | 2010-11-25 | ビオマリン アイジーエー リミテッド | デュシェンヌ型筋ジストロフィーの治療のための薬物併用 |
GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
HUE036519T2 (hu) | 2007-08-13 | 2018-07-30 | Monsanto Technology Llc | Készítmények és eljárások nematódák irtására |
EP2193126B1 (en) | 2007-10-04 | 2015-06-24 | Merck Serono S.A. | Oxadiazole diaryl compounds |
CA2696863C (en) * | 2007-10-04 | 2016-10-18 | Anna Quattropani | Oxadiazole derivatives |
AU2008310734B2 (en) | 2007-10-10 | 2014-06-05 | Parion Sciences, Inc. | Delivering osmolytes by nasal cannula |
PL2217572T3 (pl) | 2007-11-16 | 2014-04-30 | Vertex Pharma | Modulatory izochinolinowe transporterów zawierających kasetę wiążącą ATP |
JP5645217B2 (ja) | 2007-12-07 | 2014-12-24 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | 5,6−二置換オキシンドール誘導体およびバソプレッシン依存性疾患を治療するためのこれらの使用 |
WO2010009775A1 (de) | 2007-12-07 | 2010-01-28 | Abbott Gmbh & Co. Kg | Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen |
RU2484090C2 (ru) * | 2007-12-07 | 2013-06-10 | Эбботт Гмбх Унд Ко.Кг | 5-галогензамещенные производные оксиндола и их применение для лечения вазопрессинзависимых заболеваний |
US8703775B2 (en) * | 2007-12-07 | 2014-04-22 | AbbVie Deutschland GmbH & Co. KG | Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses |
SG186638A1 (en) | 2007-12-07 | 2013-01-30 | Vertex Pharma | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
KR20100110834A (ko) * | 2007-12-21 | 2010-10-13 | 메르크 세로노 에스. 에이. | 트리아졸 옥사다이아졸 유도체 |
WO2009081891A1 (ja) * | 2007-12-25 | 2009-07-02 | Kissei Pharmaceutical Co., Ltd. | 新規なカテコール誘導体、それを含有する医薬組成物およびそれらの用途 |
EP2254572B1 (en) * | 2008-02-07 | 2013-10-16 | Massachusetts Eye & Ear Infirmary | Compounds that enhance atoh-1 expression |
ES2442945T3 (es) | 2008-03-31 | 2014-02-14 | Vertex Pharmaceuticals Inc. | Derivados de piridilo como moduladores del CFTR |
US8236838B2 (en) * | 2008-04-21 | 2012-08-07 | Institute For Oneworld Health | Compounds, compositions and methods comprising isoxazole derivatives |
US20100099677A1 (en) * | 2008-04-21 | 2010-04-22 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Thiazole Derivatives |
US20090264471A1 (en) * | 2008-04-21 | 2009-10-22 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Triazole Derivatives |
WO2009131954A2 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising oxadiazole derivatives |
WO2009131957A2 (en) | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising oxadiazole derivatives |
WO2009131947A2 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyridazine derivatives |
WO2009131958A2 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising triazine derivatives |
WO2010033626A1 (en) * | 2008-09-19 | 2010-03-25 | Institute For Oneworld Health | Compounds, compositions and methods comprising imidazole and triazole derivatives |
PT2307381T (pt) * | 2008-06-09 | 2021-03-15 | Univ Muenchen Ludwig Maximilians | Novas drogas para inibir a agregação de proteínas envolvidas em doenças relacionadas com a agregação de proteínas e/ou doenças neurodegenerativas |
CN102076670B (zh) * | 2008-06-24 | 2013-05-22 | Irm责任有限公司 | 调节g蛋白偶联受体的化合物和方法 |
WO2010093650A2 (en) * | 2009-02-10 | 2010-08-19 | Divergence, Inc. | Compositions and methods for controlling nematodes |
JP5620129B2 (ja) | 2009-03-19 | 2014-11-05 | 富士フイルム株式会社 | 光学フィルム、位相差板、楕円偏光板、液晶表示装置、及び化合物 |
US8511216B2 (en) * | 2009-03-30 | 2013-08-20 | Kanzaki Kokyukoki Mfg. Co., Ltd. | Hydraulic actuator unit |
US8343976B2 (en) * | 2009-04-20 | 2013-01-01 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyrazole derivatives |
EP2251437B1 (en) | 2009-05-13 | 2013-12-04 | Hannelore Breitenbach-Koller | Method for identifying compounds that control the translational activity of ribosomal proteins in differential mRNA expression |
WO2010138600A2 (en) | 2009-05-29 | 2010-12-02 | Abbott Laboratories | Pharmaceutical compositions for the treatment of pain |
AR076984A1 (es) | 2009-06-08 | 2011-07-20 | Merck Serono Sa | Derivados de pirazol oxadiazol |
US9849146B2 (en) * | 2009-07-20 | 2017-12-26 | Rutgers, The State University Of New Jersey | Inhibition of nonsense mediated mRNA decay by drugs that prevent hypusination of eukaryotic initiation factor 5A |
US8535482B2 (en) * | 2009-08-05 | 2013-09-17 | International Paper Company | Dry fluff pulp sheet additive |
PT2498610T (pt) | 2009-11-13 | 2018-06-19 | Celgene Int Ii Sarl | Moduladores seletivos de recetor de esfingosina 1 fosfato e métodos de síntese quiral |
MY160907A (en) * | 2009-11-13 | 2017-03-31 | Receptos Inc | Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
ES2845449T3 (es) | 2010-03-25 | 2021-07-26 | Vertex Pharma | Dispersión sólida de forma amorfa de (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-il)-N-(1-(2,3-dihidroxipropil)-6-fluoro-2(1-hidroxi-2-metilpropan-2-il)-1h-indol-5il)-ciclopropanocarboxamida |
RU2592368C2 (ru) | 2010-04-07 | 2016-07-20 | Вертекс Фармасьютикалз Инкорпорейтед | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, ВКЛЮЧАЮЩИЕ 3-(2, 2-ДИФТОРБЕНЗО[d][1, 3]ДИОКСОЛ-5-ИЛ)ЦИКЛОПРОПАНКАРБОКСАМИДО)-3-МЕТИЛПИРИДИН-2-ИЛ)БЕНЗОЙНУЮ КИСЛОТУ, И ИХ ВВЕДЕНИЕ |
TWI549950B (zh) | 2010-04-07 | 2016-09-21 | 維泰克斯製藥公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]二氧雜環戊烯-5-基)環丙烷甲醯胺基)-3-甲基吡啶-2-基)苯甲酸之固體形式 |
EP3381899B1 (en) | 2010-04-22 | 2021-01-06 | Vertex Pharmaceuticals Incorporated | Intermediate compound for process of producing cycloalkylcarboxamido-indole compounds |
US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
PL2600865T3 (pl) * | 2010-08-05 | 2019-05-31 | Institut National De La Sante Et De La Rech Medicale | Związek użyteczny do leczenia chorób, w których pośredniczy mutacja nonsensowna oraz kompozycje farmaceutyczne zawierające wymieniony związek |
CA2808501A1 (en) | 2010-08-23 | 2012-03-01 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof |
ES2758841T3 (es) | 2011-05-13 | 2020-05-06 | Celgene Int Ii Sarl | Moduladores heterocíclicos selectivos del receptor de la esfingosina-1-fosfato |
WO2012170677A1 (en) | 2011-06-07 | 2012-12-13 | Parion Sciences, Inc. | Methods of treatment |
US8945605B2 (en) | 2011-06-07 | 2015-02-03 | Parion Sciences, Inc. | Aerosol delivery systems, compositions and methods |
US20140094465A1 (en) * | 2011-06-10 | 2014-04-03 | N30 Pharmaceuticals, Inc. | Compounds as S-Nitrosoglutathione Reductase Inhibitors |
AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
KR101314488B1 (ko) * | 2011-09-08 | 2013-10-07 | 중앙대학교 산학협력단 | 신경줄기세포 분화조절제용 신규 옥사디아졸 유도체 및 이의 의학적 용도 |
SI2776427T1 (sl) | 2011-11-08 | 2017-05-31 | Vertex Pharmaceuticals Incorporated | Modulatorji prenašalcev ATP-vezavne kasete |
ES2742277T3 (es) | 2012-01-25 | 2020-02-13 | Vertex Pharma | Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-ilo) ciclopropano carboxamido)-3metilpiridin-2-ilo)benzoico y su administración |
EP2828249B1 (en) * | 2012-03-23 | 2018-10-10 | The Regents of The University of California | Premature-termination-codons readthrough compounds |
BR112014029329A2 (pt) | 2012-05-29 | 2017-06-27 | Parion Sciences Inc | aminoamidas semelhantes ao dendrímero possuindo atividade bloqueadora de canal de sódio para o tratamento de olho seco e outras doenças mucosais |
US9040711B2 (en) | 2012-07-02 | 2015-05-26 | Monsanto Technology Llc | Processes for the preparation of 3,5-disubstituted-1,2,4-oxadiazoles |
EP2872122A1 (en) | 2012-07-16 | 2015-05-20 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
AU2013337730B2 (en) | 2012-11-02 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of CFTR mediated diseases |
BR112015013535A2 (pt) | 2012-12-13 | 2017-07-11 | Novartis Ag | pirimido [4,5-b]quinolina-4,5 (3h,10h)-dionas como supressores de mutação sem sentido |
AU2013363215B2 (en) | 2012-12-17 | 2018-03-01 | Parion Sciences, Inc. | 3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds |
ES2674665T3 (es) | 2012-12-17 | 2018-07-03 | Parion Sciences, Inc. | Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida |
EP3150585A1 (en) | 2012-12-17 | 2017-04-05 | Parion Sciences, Inc. | Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity |
TWI695717B (zh) * | 2014-03-06 | 2020-06-11 | 美商 Ptc 治療公司 | 1,2,4-二唑苯甲酸之鹽及醫藥組合物 |
MX2016013027A (es) | 2014-04-04 | 2017-05-23 | Del Mar Pharmaceuticals | Uso de dianhidrogalactitol y analogos o derivados del mismo para tratar cancer de celulas no pequeñas del pulmon y cancer de ovario. |
RS57476B9 (sr) | 2014-04-15 | 2021-10-29 | Vertex Pharma | Farmaceutske kompozicije za lečenje bolesti posredovanih transmembranskim regulatorom provodljivosti cistične fibroze |
AP2016009545A0 (en) | 2014-06-03 | 2016-11-30 | Novartis Ag | Naphthyridinedione derivatives |
US9896448B2 (en) | 2014-06-03 | 2018-02-20 | Novartis Ag | Pyrimido[4,5-b]quinoline-4,5(3H, 10H)-dione derivatives |
CN106414443B (zh) | 2014-06-03 | 2018-10-26 | 诺华股份有限公司 | 吡啶并嘧啶二酮衍生物 |
CN105461650B (zh) * | 2014-09-12 | 2018-04-13 | 杭州普晒医药科技有限公司 | 一种噁二唑化合物的溶剂化物及其制备方法 |
KR102336926B1 (ko) | 2014-10-06 | 2021-12-08 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정제 |
CN104292180A (zh) * | 2014-10-12 | 2015-01-21 | 湖南华腾制药有限公司 | 一种恶二唑衍生物的制备方法 |
WO2016073470A1 (en) * | 2014-11-04 | 2016-05-12 | The University Of Kansas | Lkb1-ampk activators for therapeutic use in polycystic kidney disease |
WO2016073545A1 (en) * | 2014-11-06 | 2016-05-12 | Concert Pharmaceuticals, Inc. | Phenyloxadiazole benzoic acids |
US9994559B2 (en) * | 2014-12-17 | 2018-06-12 | King's College London | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists |
CN106316885B (zh) * | 2015-07-03 | 2019-02-12 | 普济生物科技(台州)有限公司 | 一种3-[5-(2-氟苯基)-1,2,4-噁二唑-3-基]苯甲酸的制备方法 |
JP2018531975A (ja) * | 2015-10-30 | 2018-11-01 | ピーティーシー セラピューティクス,インコーポレーテッド | てんかんの治療方法 |
WO2017087364A1 (en) | 2015-11-16 | 2017-05-26 | Ptc Therapeutics, Inc. | Hydrogen isotope-enriched analogues of 1,2,4-oxandiazole benzoic acid compounds, compositions and uses thereof |
CA3048204A1 (en) | 2015-12-23 | 2017-06-29 | Moonshot Pharma Llc | Methods for inducing an immune response |
TW201808922A (zh) * | 2016-06-20 | 2018-03-16 | 台灣神隆股份有限公司 | 製備阿塔魯仁及其中間體的方法 |
GB201610867D0 (en) | 2016-06-22 | 2016-08-03 | King's College London | Crystalline forms of a therapeutic compound and processes for their preparation |
CN106279057B (zh) * | 2016-08-15 | 2022-04-15 | 广州明药科技有限公司 | Ataluren的合成方法 |
WO2018047139A1 (en) * | 2016-09-12 | 2018-03-15 | Aurigene Discovery Technologies Limited | Compounds as modulators of tigit signalling pathway |
US11207300B2 (en) | 2016-09-13 | 2021-12-28 | Marco Cipolli | Method of treatment of Shwachman-diamond syndrome |
WO2018187479A1 (en) | 2017-04-04 | 2018-10-11 | Case Western Reserve University | Method of modulating ribonucleotide reductase |
EP3641752A4 (en) | 2017-06-22 | 2021-03-17 | Moonshot Pharma LLC | CANCER TREATMENT METHODS USING COMPOSITIONS INCLUDING AMLEXANOX AND IMMUNOMODULATORS |
US11795196B2 (en) | 2017-12-15 | 2023-10-24 | Stealth Biotherapeutics Inc. | Mitochondria-targeting peptides |
WO2020078894A1 (en) | 2018-10-15 | 2020-04-23 | Academisch Medisch Centrum | Oncotherapeutic combinations |
KR102658031B1 (ko) * | 2018-12-27 | 2024-04-18 | 제이투에이치바이오텍 (주) | 근이영양증의 치료 또는 예방에 유용한 화합물 및 이들의 의약 용도의 치료, 개선 또는 예방용 유도체 |
CN110987847B (zh) * | 2019-12-11 | 2021-02-19 | 苏州今蓝纳米科技有限公司 | 1,3,4-噁二唑衍生物在检测酸以及数据加密和储存中的应用 |
CN111675672A (zh) * | 2020-05-12 | 2020-09-18 | 石家庄市度智医药科技有限公司 | 一种制备阿塔鲁伦的方法 |
CN113045510B (zh) * | 2021-03-31 | 2022-05-27 | 北京大学生命科学华东产业研究院 | 一种阿塔鲁伦的制备方法 |
EP4230196A1 (en) | 2022-02-21 | 2023-08-23 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of dystrophinopathies |
US11932632B1 (en) | 2023-10-13 | 2024-03-19 | King Faisal University | N'-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzo[d][1,3]dioxole-5 carboximidamide as an antimicrobial compound |
US11958814B1 (en) | 2023-11-02 | 2024-04-16 | King Faisal University | 3-(4-nitrophenyl)-5-((2-isopropyl-5-methylphenoxy)methyl)-1,2,4-oxadiazole as an anti-cancer and antimicrobial compound |
Family Cites Families (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL291628A (da) * | 1962-04-17 | |||
US3325446A (en) | 1964-04-17 | 1967-06-13 | Allied Chem | Stabilized halogen-containing olefin polymer compositions and stabilizers therefor |
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4022901A (en) * | 1975-03-05 | 1977-05-10 | E. R. Squibb & Sons, Inc. | 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles |
JPS51143669A (en) | 1975-06-06 | 1976-12-10 | Takeda Chem Ind Ltd | A process for preparing 1,2,4- oxadiazole derivatives |
US4016170A (en) | 1975-07-28 | 1977-04-05 | Sandoz, Inc. | Oxadiazolyl benzamides |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4135910A (en) * | 1977-05-12 | 1979-01-23 | Monsanto Company | Oxadiazol-3-yl-benzoates as plant growth regulants |
US4166732A (en) | 1977-05-12 | 1979-09-04 | Monsanto Company | Oxadiazol-5-yl-benzoates |
US4165910A (en) * | 1977-10-25 | 1979-08-28 | Bunker Ramo Corporation | Electrical connector |
AU531759B2 (en) | 1978-04-17 | 1983-09-08 | Ici Ltd. | Electrostatic spraying |
US4268299A (en) | 1978-08-17 | 1981-05-19 | Monsanto Company | Method and composition for plant growth regulation containing trifluoromethyl 1,3,4 oxadiazol benzoates |
US4210762A (en) | 1978-08-17 | 1980-07-01 | Monsanto Company | 2[5-(3-Trifluoromethylphenyl)-1,3,4-oxadiazol-2-yl] benzoates |
DE3173083D1 (en) | 1980-03-22 | 1986-01-16 | Fbc Ltd | Pesticidal heterocyclic compounds, processes for preparing them, compositions containing them, and their use |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
GB8504253D0 (en) | 1985-02-19 | 1985-03-20 | Ici Plc | Electrostatic spraying apparatus |
DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
GB9225098D0 (en) | 1992-12-01 | 1993-01-20 | Coffee Ronald A | Charged droplet spray mixer |
GB9226717D0 (en) | 1992-12-22 | 1993-02-17 | Coffee Ronald A | Induction-operated electro-hydrodynamic spray device with means of modifying droplet trajectories |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
DE4320801A1 (de) | 1993-06-23 | 1995-01-05 | Fahlberg List Pharma Gmbh | 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel |
US5484944A (en) | 1993-10-27 | 1996-01-16 | Neurogen Corporation | Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands |
GB9406171D0 (en) | 1994-03-29 | 1994-05-18 | Electrosols Ltd | Dispensing device |
GB9406255D0 (en) | 1994-03-29 | 1994-05-18 | Electrosols Ltd | Dispensing device |
TW343965B (en) | 1994-03-30 | 1998-11-01 | Hoffmann La Roche | Novel mono- and bicyclic DNA gyrase inhibitors |
GB9410658D0 (en) | 1994-05-27 | 1994-07-13 | Electrosols Ltd | Dispensing device |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
US6071700A (en) * | 1995-01-20 | 2000-06-06 | University Of Massachusetts | Heterologous polypeptide production in the absence of nonsense-mediated MRNA decay functions |
US5950619A (en) | 1995-03-14 | 1999-09-14 | Siemens Aktiengesellschaft | Ultrasonic atomizer device with removable precision dosating unit |
DE69621604T2 (de) | 1995-03-14 | 2002-11-28 | Siemens Ag | Ultraschall-zerstäuber mit abnehmbarer präzisionsdosiereinheit |
SK30198A3 (en) | 1995-09-07 | 1998-08-05 | Novartis Ag | Substituted phosphinic compounds and their use as pharmaceuticals |
WO1997039745A1 (en) | 1996-04-19 | 1997-10-30 | Sloan-Kettering Institute For Cancer Research | Use of inhaled retinoids in the prevention of cancer |
CN1216534A (zh) * | 1996-04-26 | 1999-05-12 | 日本曹达株式会社 | 杂环取代的新颖苯衍生物和除草剂 |
DE19620041A1 (de) * | 1996-05-17 | 1998-01-29 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
US6034106A (en) | 1996-06-07 | 2000-03-07 | Merck & Co., Inc. | Oxadiazole benzenesulfonamides as selective β3 Agonist for the treatment of Diabetes and Obesity |
AU712057B2 (en) | 1996-06-07 | 1999-10-28 | Merck & Co., Inc. | Oxadiazole benzenesulfonamides as selective beta3 agonists for the treatment of diabetes and obesity |
DE19626318A1 (de) | 1996-07-01 | 1998-01-08 | Basf Ag | Farbstoffmischungen, enthaltend Polyazofarbstoffe |
ZA98371B (en) | 1997-01-31 | 1999-07-16 | Du Pont | Genetically transformed plants demonstrating resistance to porphyrinogen biosynthesis-inhibiting herbicides. |
ES2329739T3 (es) | 1997-04-07 | 2009-11-30 | Georgetown University | Analogos de cocaina. |
US6004933A (en) | 1997-04-25 | 1999-12-21 | Cortech Inc. | Cysteine protease inhibitors |
US5954047A (en) | 1997-10-17 | 1999-09-21 | Systemic Pulmonary Development, Ltd. | Methods and apparatus for delivering aerosolized medication |
AU9647998A (en) * | 1997-10-27 | 1999-05-17 | Nippon Soda Co., Ltd. | Novel benzoylpyrazole derivatives and herbicides |
CN1292714B (zh) | 1998-03-16 | 2012-08-01 | 诺瓦帝斯公司 | 气溶胶化活性剂的输送 |
IL139187A0 (en) | 1998-04-23 | 2001-11-25 | Cortech Inc | Cysteine protease inhibitors |
ID28385A (id) | 1998-10-08 | 2001-05-17 | Smithkline Beecham Plc | Turunan-turunan tetrahidrobenzazepina yang berguna sebagai modulator reseptor d3 dopamina (bahan antipsikotik) |
ATE259803T1 (de) | 1998-10-09 | 2004-03-15 | Janssen Pharmaceutica Nv | 4,5-dehydroisoxazole derivate und ihre pharmazeutische verwendung |
AU1455500A (en) | 1998-10-29 | 2000-05-22 | Trega Biosciences, Inc. | Oxadiazole, thiadiazole and triazole derivatives and combinatorial libraries thereof |
CZ20012277A3 (cs) | 1998-12-23 | 2001-11-14 | Smithkline Beecham Corporation | Inhibitory proteázy |
WO2000058304A1 (fr) | 1999-03-26 | 2000-10-05 | Shionogi & Co., Ltd. | Derives sulfonamides heterocycliques |
WO2000058280A1 (fr) | 1999-03-26 | 2000-10-05 | Shionogi & Co., Ltd. | Derives de sulfonamide carbocyclique |
AU3196200A (en) | 1999-03-26 | 2000-10-16 | Shionogi & Co., Ltd. | Beta-amino acid derivatives |
CN1356977A (zh) | 1999-05-17 | 2002-07-03 | 诺沃挪第克公司 | 胰高血糖素拮抗剂/反向激动剂 |
UA71971C2 (en) | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
JP2001247569A (ja) | 1999-08-12 | 2001-09-11 | Japan Tobacco Inc | ピロリジン誘導体又はピペリジン誘導体及びその医薬用途 |
US6660753B2 (en) * | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
US6458538B1 (en) | 1999-12-14 | 2002-10-01 | Ptc Therapeutics, Inc. | Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay |
WO2001066534A2 (en) | 2000-03-09 | 2001-09-13 | Abbott Laboratories | Cyclic and bicyclic diamino histamine-3 receptor antagonists |
JP2003528106A (ja) | 2000-03-22 | 2003-09-24 | メルク フロスト カナダ アンド カンパニー | Ptp−1b阻害薬としての硫黄置換アリールジフルオロメチルホスホン酸類 |
WO2001083464A1 (fr) * | 2000-04-21 | 2001-11-08 | Shionogi & Co., Ltd. | Derives d'oxadiazole efficaces en matiere de traitement ou de prevention d'etats pathologiques glomerulaire |
GB0011089D0 (en) * | 2000-05-08 | 2000-06-28 | Black James Foundation | Gastrin and cholecystokinin receptor ligands (11) |
CA2409827C (en) | 2000-05-22 | 2010-06-01 | Aventis Pharmaceuticals Products Inc. | Arylmethylamine derivatives for use as tryptase inhibitors |
CN1328143A (zh) | 2000-06-12 | 2001-12-26 | 上海博德基因开发有限公司 | 一种新的多肽——人甲基化-dna-蛋白-半胱氨酸甲基转移酶13和编码这种多肽的多核苷酸 |
JP2002105073A (ja) | 2000-09-27 | 2002-04-10 | Shionogi & Co Ltd | 新規マトリックスメタロプロテアーゼ阻害剤 |
AUPR362001A0 (en) | 2001-03-08 | 2001-04-05 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
CA2342432A1 (en) | 2001-03-28 | 2002-09-28 | Christopher Norbert Johnson | Novel compound |
GB0108102D0 (en) * | 2001-03-30 | 2001-05-23 | Pfizer Ltd | Compounds |
BR0209054A (pt) | 2001-04-19 | 2004-04-20 | Bayer Ag | Arilsulfonamidas como agentes antivirais |
KR20040004705A (ko) * | 2001-06-08 | 2004-01-13 | 시토비아 인크. | 카스파제의 활성제 및 아폽토시스의 유도제로서의 치환된3-아릴-5-아릴-[1,2,4]-옥사디아졸과 유사체 및 이의 용도 |
JP2003081832A (ja) * | 2001-06-26 | 2003-03-19 | Takeda Chem Ind Ltd | レチノイド関連受容体機能調節剤 |
GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
MY151199A (en) * | 2001-11-02 | 2014-04-30 | Rigel Pharmaceuticals Inc | Substituted diphenyl heterocycles useful for treating hcv infection |
AR041508A1 (es) | 2002-08-09 | 2005-05-18 | Astra Ab | Compuestos con actividad en los receptores de glutamato metabotropicos |
AU2003264018A1 (en) | 2002-08-09 | 2004-02-25 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
GB0303503D0 (en) | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
KR100729883B1 (ko) | 2003-03-28 | 2007-06-18 | 화이자 프로덕츠 인코포레이티드 | 죽상경화증 및 비만증을 치료하기 위한 cetp억제제로서의 1,2,4-치환된 1,2,3,4-테트라하이드로- 및1,2-디하이드로-퀴놀린 및1,2,3,4-테트라하이드로-퀴녹살린 유도체 |
ZA200508298B (en) * | 2003-04-11 | 2007-01-31 | Ptc Therapeutics Inc | 1,2,4-oxadiazole benzoic acid compounds |
US20050075375A1 (en) | 2003-05-14 | 2005-04-07 | Anadys Pharmaceuticals, Inc. | Heterocyclic compounds for treating hepatitis C virus |
WO2005060961A2 (en) | 2003-12-18 | 2005-07-07 | Astrazeneca Ab | Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd) |
US7745630B2 (en) | 2003-12-22 | 2010-06-29 | Justin Stephen Bryans | Triazolyl piperidine arginine vasopressin receptor modulators |
WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
EP1799659A1 (en) | 2004-10-13 | 2007-06-27 | PTC Therapeutics, Inc. | Compounds for nonsense suppression, and methods for their use |
US8716321B2 (en) | 2005-04-08 | 2014-05-06 | Ptc Therapeutics, Inc. | Methods for dosing an orally active 1,2,4-oxadiazole |
MX2008012515A (es) | 2006-03-30 | 2008-11-19 | Ptc Therapeutics Inc | Metodos para la produccion de proteina funcional a partir de adn que tiene una mutacion sin sentido y el tratamiento de trastornos asociados con la misma. |
WO2007123848A2 (en) | 2006-04-19 | 2007-11-01 | Brown University | Therapeutic compositions containing modified class i slrp proteins |
NZ598012A (en) * | 2006-09-08 | 2013-08-30 | Ptc Therapeutics Inc | Processes for the preparation of 1,2,4-oxadiazole benzoic acids |
CL2007002743A1 (es) | 2006-09-25 | 2008-07-11 | Pct Therapeutics Inc Soc Organ | Forma cristalina del acido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]-benzoico; composicion farmaceutica que comprende a dicha forma cristalina; y su uso para modular la terminacion prematura de traslado o decaimiento de marn, tales como carcicoma. |
SI2073805T1 (sl) | 2006-10-12 | 2015-10-30 | Ptc Therapeutics, Inc. | Postopki za odmerjanje peroralno aktivnega 1,2,4-oksadiazola za zdravljenje supresije nesmiselnih mutacij |
WO2008127364A2 (en) | 2006-10-13 | 2008-10-23 | Myriad Genetics, Inc. | Antiviral compounds and use thereof |
US20110177999A1 (en) | 2007-08-09 | 2011-07-21 | Vertex Pharmaceuticals Incorporated | Therapeutic Combinations Useful in Treating CFTR Related Diseases |
CA2696863C (en) | 2007-10-04 | 2016-10-18 | Anna Quattropani | Oxadiazole derivatives |
AU2008317566B2 (en) | 2007-10-26 | 2014-05-01 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
ES2594302T3 (es) | 2007-12-17 | 2016-12-19 | The Regents Of The University Of Michigan | Composiciones y procedimientos de tratamiento y prevención de deficiencias de músculo esquelético |
CN102076670B (zh) | 2008-06-24 | 2013-05-22 | Irm责任有限公司 | 调节g蛋白偶联受体的化合物和方法 |
PL2344129T3 (pl) | 2008-10-07 | 2018-07-31 | Horizon Orphan Llc | Formulacje fluorochinolonu w aerozolu dla poprawy właściwości farmakokinetycznych |
RU2398770C1 (ru) | 2009-03-27 | 2010-09-10 | Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН) | Меченная тритием 3-[5-(2-фторфенил)-1,2,4-оксадиазол-3-ил]бензойная кислота |
-
2004
- 2004-04-09 ZA ZA200508298A patent/ZA200508298B/en unknown
- 2004-04-09 HU HUE21169137A patent/HUE059464T2/hu unknown
- 2004-04-09 EP EP04759404.9A patent/EP1618098B1/en not_active Expired - Lifetime
- 2004-04-09 PT PT141888164T patent/PT2910551T/pt unknown
- 2004-04-09 PT PT211691373T patent/PT3889142T/pt unknown
- 2004-04-09 DK DK04759404.9T patent/DK1618098T3/da active
- 2004-04-09 HU HUE17204895A patent/HUE047569T2/hu unknown
- 2004-04-09 PL PL16170630T patent/PL3103800T3/pl unknown
- 2004-04-09 ES ES16170630.4T patent/ES2679108T3/es not_active Expired - Lifetime
- 2004-04-09 EP EP22178089.3A patent/EP4101846B1/en not_active Expired - Lifetime
- 2004-04-09 DK DK19174887.0T patent/DK3549936T3/da active
- 2004-04-09 EP EP16170630.4A patent/EP3103800B1/en not_active Expired - Lifetime
- 2004-04-09 CN CN200480015905.0A patent/CN1802360B/zh not_active Expired - Lifetime
- 2004-04-09 PT PT191748870T patent/PT3549936T/pt unknown
- 2004-04-09 DK DK21169137.3T patent/DK3889142T3/da active
- 2004-04-09 HU HUE19209758A patent/HUE055434T2/hu unknown
- 2004-04-09 PL PL04759404T patent/PL1618098T3/pl unknown
- 2004-04-09 PT PT47594049T patent/PT1618098E/pt unknown
- 2004-04-09 NZ NZ543263A patent/NZ543263A/en unknown
- 2004-04-09 WO PCT/US2004/011106 patent/WO2004091502A2/en active Application Filing
- 2004-04-09 SI SI200432521T patent/SI3889142T1/sl unknown
- 2004-04-09 BR BRPI0409319A patent/BRPI0409319B8/pt active IP Right Grant
- 2004-04-09 ES ES21169137T patent/ES2926542T3/es not_active Expired - Lifetime
- 2004-04-09 PT PT192097582T patent/PT3632902T/pt unknown
- 2004-04-09 ES ES19209758T patent/ES2887054T3/es not_active Expired - Lifetime
- 2004-04-09 ES ES04759404.9T patent/ES2528195T3/es not_active Expired - Lifetime
- 2004-04-09 PT PT161706304T patent/PT3103800T/pt unknown
- 2004-04-09 TR TR2017/06226T patent/TR201706226T4/tr unknown
- 2004-04-09 DK DK19209758.2T patent/DK3632902T3/da active
- 2004-04-09 SI SI200432512T patent/SI3549936T1/sl unknown
- 2004-04-09 EP EP21169137.3A patent/EP3889142B1/en not_active Expired - Lifetime
- 2004-04-09 SI SI200432389A patent/SI2910551T1/sl unknown
- 2004-04-09 AU AU2004229487A patent/AU2004229487B9/en not_active Expired
- 2004-04-09 JP JP2006509896A patent/JP4851933B2/ja not_active Expired - Lifetime
- 2004-04-09 MX MXPA05010747A patent/MXPA05010747A/es active IP Right Grant
- 2004-04-09 EP EP19209758.2A patent/EP3632902B1/en not_active Expired - Lifetime
- 2004-04-09 EP EP17204895.1A patent/EP3345895B1/en not_active Expired - Lifetime
- 2004-04-09 ES ES19174887T patent/ES2881198T3/es not_active Expired - Lifetime
- 2004-04-09 HU HUE19174887A patent/HUE055056T2/hu unknown
- 2004-04-09 PL PL21169137.3T patent/PL3889142T3/pl unknown
- 2004-04-09 HU HUE16170630A patent/HUE039026T2/hu unknown
- 2004-04-09 DK DK14188816.4T patent/DK2910551T3/da active
- 2004-04-09 SI SI200432445T patent/SI3103800T1/sl unknown
- 2004-04-09 PL PL17204895T patent/PL3345895T3/pl unknown
- 2004-04-09 DK DK17204895.1T patent/DK3345895T3/da active
- 2004-04-09 DK DK16170630.4T patent/DK3103800T3/da active
- 2004-04-09 US US10/822,259 patent/US6992096B2/en not_active Expired - Lifetime
- 2004-04-09 KR KR1020057019319A patent/KR101134188B1/ko active IP Right Grant
- 2004-04-09 CN CN201410119475.2A patent/CN104056278B/zh not_active Expired - Lifetime
- 2004-04-09 EA EA200501601A patent/EA009120B1/ru active Protection Beyond IP Right Term
- 2004-04-09 SI SI200432514T patent/SI3632902T1/sl unknown
- 2004-04-09 SI SI200432484T patent/SI3345895T1/sl unknown
- 2004-04-09 UA UAA200510644A patent/UA84420C2/ru unknown
- 2004-04-09 PL PL14188816T patent/PL2910551T3/pl unknown
- 2004-04-09 PT PT172048951T patent/PT3345895T/pt unknown
- 2004-04-09 EP EP17153046.2A patent/EP3178816A1/en not_active Withdrawn
- 2004-04-09 PL PL19209758T patent/PL3632902T3/pl unknown
- 2004-04-09 PL PL19174887T patent/PL3549936T3/pl unknown
- 2004-04-09 HU HUE14188816A patent/HUE031794T2/en unknown
- 2004-04-09 EP EP14188816.4A patent/EP2910551B1/en not_active Expired - Lifetime
- 2004-04-09 EP EP19174887.0A patent/EP3549936B1/en not_active Expired - Lifetime
- 2004-04-09 ES ES14188816.4T patent/ES2624610T3/es not_active Expired - Lifetime
- 2004-04-09 CA CA2521992A patent/CA2521992C/en not_active Expired - Lifetime
- 2004-04-09 SI SI200432222T patent/SI1618098T1/sl unknown
- 2004-04-09 ES ES17204895T patent/ES2770035T3/es not_active Expired - Lifetime
-
2005
- 2005-01-24 US US11/042,652 patent/US7772259B2/en active Active
- 2005-09-29 US US11/241,700 patent/US7202262B2/en not_active Expired - Lifetime
- 2005-10-10 IL IL171343A patent/IL171343A/en active IP Right Grant
- 2005-11-09 MA MA28594A patent/MA27802A1/fr unknown
- 2005-11-10 NO NO20055314A patent/NO332843B1/no active Protection Beyond IP Right Term
- 2005-11-10 CR CR8086A patent/CR8086A/es unknown
-
2006
- 2006-03-06 US US11/370,130 patent/US7419991B2/en active Active
- 2006-03-06 US US11/370,229 patent/US7304080B2/en not_active Expired - Lifetime
-
2007
- 2007-01-08 HK HK07100245.6A patent/HK1093979A1/xx not_active IP Right Cessation
- 2007-03-14 US US11/724,408 patent/US7683082B2/en active Active - Reinstated
-
2010
- 2010-01-21 US US12/691,005 patent/US8129540B2/en not_active Expired - Lifetime
- 2010-02-17 US US12/707,404 patent/US8017636B2/en not_active Expired - Lifetime
- 2010-03-08 US US12/719,443 patent/US8227494B2/en not_active Expired - Lifetime
-
2011
- 2011-07-15 JP JP2011156613A patent/JP5436500B2/ja not_active Expired - Lifetime
- 2011-08-18 US US13/212,221 patent/US8163782B2/en not_active Expired - Fee Related
-
2012
- 2012-03-23 US US13/427,932 patent/US8299105B2/en not_active Expired - Lifetime
- 2012-06-22 US US13/530,139 patent/US8486982B2/en not_active Expired - Lifetime
-
2013
- 2013-03-11 IL IL225161A patent/IL225161A/en active IP Right Grant
- 2013-06-19 US US13/921,269 patent/US8796322B2/en not_active Expired - Lifetime
-
2014
- 2014-06-18 US US14/307,747 patent/US8975287B2/en not_active Expired - Lifetime
-
2015
- 2015-01-16 CY CY20151100039T patent/CY1115870T1/el unknown
- 2015-01-28 US US14/607,132 patent/US9205088B2/en not_active Expired - Lifetime
- 2015-02-03 NO NO2015002C patent/NO2015002I1/no not_active IP Right Cessation
- 2015-03-18 HK HK15102788.5A patent/HK1202254A1/xx not_active IP Right Cessation
- 2015-04-16 HU HUS1500021C patent/HUS1500021I1/hu unknown
- 2015-04-17 CY CY2015017C patent/CY2015017I2/el unknown
- 2015-04-20 LU LU92698C patent/LU92698I2/xx unknown
- 2015-04-20 BE BE2015C025C patent/BE2015C025I2/fr unknown
- 2015-04-21 FR FR15C0030C patent/FR15C0030I2/fr active Active
- 2015-11-13 US US14/940,345 patent/US9861617B2/en active Active
-
2016
- 2016-02-24 HK HK16102106.9A patent/HK1214253A1/zh not_active IP Right Cessation
-
2017
- 2017-05-03 CY CY20171100480T patent/CY1119001T1/el unknown
- 2017-12-04 US US15/830,405 patent/US10071081B2/en not_active Expired - Lifetime
-
2018
- 2018-07-20 CY CY20181100761T patent/CY1120446T1/el unknown
- 2018-12-21 HK HK18116432.2A patent/HK1257517A1/zh not_active IP Right Cessation
-
2020
- 2020-01-23 CY CY20201100063T patent/CY1122659T1/el unknown
-
2021
- 2021-08-30 CY CY20211100766T patent/CY1124464T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR15C0030I2 (fr) | Composes d'acide benzoique 1,2,4-oxadiazole et utilisation de ceux-ci dans la suppression non-sens et le traitement de maladies | |
CY2008019I1 (el) | Υποκατεστημενες οξαζολιδινονες και η χρηση των στο πεδιο της πηξης αιματος | |
EE200300485A (et) | Tiohüdantoinid ja nende kasutamine diabeedi raviks | |
FR2869541B1 (fr) | Utilisation d'une composition comprenant du d-mannoheptulose et/ou du perseitol dans le traitement et la prevention des maladies liees a une modification de l'immunite innee | |
FR13C0060I2 (fr) | Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques | |
ZA200300788B (en) | Improvements in and relating to the use of honey in dressings. | |
EP1769791A3 (en) | Treatment of Alzheimer's disease with cell cycle inhibitors | |
DE60023128D1 (de) | Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen | |
FR2854074B1 (fr) | Utilisation de l'ivermectine pour le traitement de desordres dermatologiques | |
PL1641918T3 (pl) | Komórki poporodowe do zastosowania w leczeniu choroby serca i układu krążenia | |
ATE374204T1 (de) | Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen | |
FR2812197B1 (fr) | Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches | |
MA29084B1 (fr) | Derives d'indenyle et leur utilisation dans le traitement de troubles neurologiques | |
EE200300473A (et) | Tsüano-asendatud dihüdropürimidiinühendid ja nende kasutamine haiguste raviks | |
FR2834459B1 (fr) | Agent microbicide et composition de traitement cosmetique le contenant | |
FR2809005B1 (fr) | Utilisation du manganese dans le traitement des rides | |
ID27576A (id) | Penggunaan siklosporin dalam pengobatan penyakit-penyakit peradangan autoimun | |
DK1670482T4 (da) | Anvendelse af ciclesonid til behandlingen af respiratoriske sygdomme | |
FR2793795B1 (fr) | Isomeres de tetramides du complexe de gadolinium de l'acide (1,4,7,10-tetrazacyclododecane)1,4,7,10-tetra(2-glutarique) leur procede de preparation et leur application en imagerie medicale | |
DK1461042T3 (da) | Anvendelse af desoxypeganin til behandling af klinisk depression | |
FR2826269B1 (fr) | Utilisation de polyammonium quaternaire dans le traitement de l'acne et des desordres cutanes lies a l'hyperseborrhee | |
FR2797584B1 (fr) | Utilisation de lipides peroxydes dans le traitement ou la prevention des plaies et inflammations des muqueuses de la cavite buccale | |
AU2001296477A1 (en) | Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas | |
ITMI20031098A0 (it) | Composti utili nella terapia del morbo di alzheimer e formulazioni che li contengono | |
FR2774596B1 (fr) | Utilisation de composes selenies dans la prevention et le traitement de la maladie d'alzheimer |